Idiopathic pulmonary fibrosis

The PBS subsidises nintedanib and pirfenidone for patients with idiopathic pulmonary fibrosis (IPF).

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with nintedanib and pirfenidone under the National Health Act 1953, section 85 for patients with IPF.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing nintedanib and pirfenidone.

Authority applications

Applying for initial treatment

Apply for initial authority approval to prescribe PBS subsidised nintedanib or pirfenidone to treat IPF in writing and either:

All written applications must include completed:

Applying for a change or recommencement of treatment

Apply to change or recommence PBS subsidised nintedanib or pirfenidone to treat IPF can be made either:

Applying for continuing treatment

Apply for continuing authority approval to prescribe PBS subsidised nintedanib or pirfenidone to treat IPF can be made either:

More information

Call the PBS Complex Drugs Programs enquiry line for further information.

Page last updated: 1 May 2022